Skip to main content

Table 3 Results of the cost per response analysis at 16, 24, and 52 weeks

From: A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study

Outcome Parameter Week Overall Secukinumab Ustekinumab Adalimumab originator Ixekizumab
PASI 75 Number of evaluated patients (N) 16 405 165 118 38 49
24 380 154 105 46 38
52 551 241 145 63 65
Response rate (%) 16 86% 95% 80% 74% 90%
24 90% 97% 87% 83% 89%
52 91% 93% 94% 87% 91%
Cost per responder ratio (€) 16 €9774 €9015 €11,689 €7848 €11,092
24 €11,652 €10,982 €13,617 €10,069 €13,710
52 €20,281 €19,932 €21,387 €18,491 €22,084
PASI 90 Number of evaluated patients (N) 16 391 162 113 36 46
24 362 150 95 45 35
52 540 238 140 62 63
Response rate (%) 16 59% 64% 56% 50% 63%
24 74% 84% 69% 67% 71%
52 75% 77% 74% 71% 81%
Cost per responder ratio (€) 16 €14,378 €13,395 €16,806 €11,560 €15,839
24 €14,213 €12,742 €17,035 €12,477 €17,172
52 €24,662 €23,978 €27,522 €22,755 €24,743
PASI 100 Number of evaluated patients (N) 16 421 172 123 38 52
24 393 158 107 48 40
52 564 243 150 66 65
Response rate (%) 16 36% 42% 29% 32% 37%
24 46% 51% 38% 56% 53%
52 53% 55% 51% 52% 58%
Cost per responder ratio (€) 16 €23,350 €20,079 €32,031 €18,312 €27,129
24 €22,674 €20,857 €30,779 €14,784 €23,268
52 €35,045 €33,419 €39,280 €31,378 €34,289
  1. PASI: Psoriasis Area Severity Index